Amgen Inc Post ASH 2020 Oncology Update Transcript
Good afternoon. My name is Sarah, and I will be your conference facilitator today for Amgen's post-ASH 2020 Annual Meeting Conference Call. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.
Okay. Great. Thank you, Sarah, and good afternoon, everybody. Thanks for joining us today for this post-ASH update. Looking forward to our discussion.
So among the data presentations we made during the scientific sessions, we presented a Phase I first-in-human study of AMG 701, which, as you know, is an extended half-life BiTE targeting BCMA in relapsed/refractory multiple myeloma. We also felt that this is a good opportunity to discuss our broader hematology/oncology strategy, including our broader BiTE portfolio, including AMG 160, targeting PSMA in prostate cancer and AMG 757, targeting DLL3 in lung cancer.
We have posted some slides on our website to guide this discussion. And also joining me today are Dr. David Reese, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
